Clinical Trials
5 trialsNCT04457778 2026-05-04
First in Human Study of M6223
EMD Serono
Phase 1 Completed
NCT03388632 2025-12-18
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04319198 2025-09-30
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
Phase 4 Completed
NCT03523390 2024-02-23
Phase I/Ib Multiple Ascending Dose Study in China
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03573544 2024-02-22
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
OBI Pharma, Inc
Phase 1/2 Terminated